These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 25417728)

  • 1. Afatinib and lung cancer.
    Jain P; Khanal R; Sharma A; Yan F; Sharma N
    Expert Rev Anticancer Ther; 2014 Dec; 14(12):1391-406. PubMed ID: 25417728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
    Brückl W; Tufman A; Huber RM
    Expert Rev Anticancer Ther; 2017 Feb; 17(2):143-155. PubMed ID: 27898252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
    Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
    J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer.
    Sharma N; Graziano S
    Cancer Treat Rev; 2018 Sep; 69():143-151. PubMed ID: 30014952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
    Cobo M; Gutiérrez V; Rodelo L; López O; Ruiz M; Godoy A
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():25-9. PubMed ID: 27426245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Management of Patients with Advanced Epidermal Growth Factor Receptor Mutation Non-small Cell Lung Cancer: Role of Afatinib and Lesson Learned for Developing Countries.
    Amin Z; Jayalie VF; Rajabto W
    Acta Med Indones; 2017 Jan; 49(1):79-88. PubMed ID: 28450659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afatinib: A Review in Advanced Non-Small Cell Lung Cancer.
    Keating GM
    Target Oncol; 2016 Dec; 11(6):825-835. PubMed ID: 27873136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].
    Vidal ÓJ
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():12-8. PubMed ID: 27426243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib.
    Liao BC; Lin CC; Yang JC
    Curr Oncol Rep; 2017 Jan; 19(1):4. PubMed ID: 28138934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mechanism of action and preclinical development of afatinib].
    Diz Taín P; González AL; García-Palomo A
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():7-11. PubMed ID: 27426242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity.
    Ueda H; Hayashi H; Kudo K; Takeda M; Nakagawa K
    Invest New Drugs; 2016 Dec; 34(6):797-799. PubMed ID: 27550238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
    Ninomiya T; Nogami N; Kozuki T; Harada D; Kubo T; Ohashi K; Kuyama S; Kudo K; Bessho A; Fukamatsu N; Fujimoto N; Aoe K; Shibayama T; Sugimoto K; Takigawa N; Hotta K; Kiura K
    Lung Cancer; 2018 Jan; 115():103-108. PubMed ID: 29290249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review.
    Yamamoto Y; Kodama K; Maniwa T; Takeda M
    J Cardiothorac Surg; 2017 Nov; 12(1):98. PubMed ID: 29169381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers.
    Chouaid C; Luciani L; LeLay K; Do P; Bennouna J; Perol M; Moro-Sibilot D; Vergnenègre A; de Pouvourville G
    J Thorac Oncol; 2017 Oct; 12(10):1496-1502. PubMed ID: 28751244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity.
    Toba H; Sakiyama S; Takizawa H; Tangoku A
    J Med Invest; 2016; 63(1-2):149-51. PubMed ID: 27040072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of afatinib for the treatment of non-small cell lung cancer.
    Barron F; de la Torre-Vallejo M; Luna-Palencia RL; Cardona AF; Arrieta O
    Expert Opin Drug Saf; 2016 Nov; 15(11):1563-1572. PubMed ID: 27633264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer.
    Rossi A; La Salvia A; Di Maio M
    Expert Rev Respir Med; 2017 Mar; 11(3):171-180. PubMed ID: 28152323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay.
    Kimura S; Tanaka K; Harada T; Liu R; Shibahara D; Kawano Y; Nakanishi Y; Okamoto I
    Cancer Sci; 2018 Nov; 109(11):3657-3661. PubMed ID: 30255614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring
    Tanaka K; Nosaki K; Otsubo K; Azuma K; Sakata S; Ouchi H; Morinaga R; Wataya H; Fujii A; Nakagaki N; Tsuruta N; Takeshita M; Iwama E; Harada T; Nakanishi Y; Okamoto I
    Oncotarget; 2017 Sep; 8(40):68123-68130. PubMed ID: 28978102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete Tumor Response with Afatinib 20 mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report.
    Giusti R; Mazzotta M; Iacono D; Lauro S; Marchetti P
    Clin Drug Investig; 2017 Jun; 37(6):581-585. PubMed ID: 28299582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.